Obesity may be erythropoietin dose-saving in hemodialysis patients

• Egile Nagusiak: Ghada M. El-Kannishy (Egilea), Abir F. Megahed (Egilea), Mona M. Tawfik (Egilea), Ghada El-Said (Egilea), Rabab T. Zakaria (Egilea), Nahed A. Mohamed (Egilea), Eman M. Taha (Egilea), Alzhraa A. Ammar (Egilea), Abeer M. Abd Eltawab (Egilea), Nagy A. Sayed-Ahmed (Egilea)
• Formatua: Liburua
• Argitaratua: The Korean Society of Nephrology, 2018-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background : In dialysis patients, the obesity-survival paradox still requires an explanation. Anemia and high doses of erythropoiesis-stimulating agents (ESAs) are associated with worse outcomes in the hemodialysis (HD) population. In the present study, we explored the relation between obesity and...